Compare GSK plc (GSK) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Kroger Co — how do they compare? GSK plc trades at $50.29 (market cap $102.60B), while Kroger Co trades at $56.16 (market cap $34.46B). The key difference: GSK plc is far larger — about 3× Kroger Co's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | KR | |
|---|---|---|
Market Cap | $102.60B | $34.46B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $75.60 |
52-Week Low | $38.22 | $55.53 |
Enterprise Value | $123.04B | $54.56B |
Dividend Yield | 3.57% | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Kroger (KR) trades at $56.15, down 0.58% on the day, reflecting recent market pressure. The stock shows mixed signals with a bearish technical outlook but solid fundamentals including a low P/S ratio of 0.24 and consistent dividend payments. Recent earnings saw a Q1 2026 miss but beats in prior quarters, while analyst consensus remains positive with a $68.25 price target. Cash flow from operations remains strong at $5.79B in 2025, supporting ongoing investments in e-commerce and digital initiatives.
The outlook for KR is cautiously optimistic. Valuation appears reasonable relative to sales, and dividend income provides stability. However, near-term risks include competitive pressures in grocery retail, margin compression from inflation, and technical bearish signals. Investors should weigh strong cash generation against earnings volatility and debt levels that have risen to 30.23% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
